Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations. (20th September 2021)

• Record Type: Journal Article
• Authors: Karbiener, Michael; Farcet, Maria R; Schwaiger, Julia; Powers, Nicholas; Lenart, James; Stewart, Joseph M; Tallman, Hema; Kreil, Thomas R
• Is Part Of: Journal of infectious diseases. Volume 224:Number 10(2021)
• Page Start: 1707
• Page End: 1711
• Publication Date: 2021-09-20
• Subjects: Primary immunodeficiency -- Secondary immunodeficiency -- SARS-CoV-2 -- SARS coronavirus 2 antibody potency -- neutralizing antibodies -- COVID-19 -- intravenous immune globulin -- immunoglobulin -- plasma -- prophylaxis -- hyperimmune globulin -- CoVIg-19; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab482
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post–coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti–SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post–COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products. Abstract : A rapidly increasing proportion of the US population, including plasma donors, now carries severe acute respiratory syndrome 2 (SARS-CoV-2) neutralizing antibodies, a consequence of earlier coronavirus disease 2019 (COVID-19) or—for many more—vaccination against it. The widely used messenger RNA vaccines induce higher antibody titers than COVID-19, and thus a proportion of immunoglobulin lots fractionated from US-origin plasma now contain SARS-CoV-2 neutralizing antibody titers even more potent than earlier produced COVID-19 hyperimmune globulin products.